MNX1-AS1 activated by TEAD4 can promote the GC process through EZH2/BTG2 and miR-6785-5p/BCL2 axes, suggesting that it was a novel and effective therapeutic target for gastric cancer (Shuai et al., 2020). Here, TEAD4 is linked to gastric cancer.